QQQ   352.59 (+1.08%)
AAPL   180.03 (+1.24%)
MSFT   325.17 (+0.55%)
META   264.98 (+0.52%)
GOOGL   122.05 (-0.37%)
AMZN   123.96 (+2.25%)
TSLA   233.08 (+3.79%)
NVDA   386.95 (+3.26%)
NIO   7.69 (-0.90%)
BABA   86.34 (+1.24%)
AMD   121.01 (+2.70%)
T   16.04 (-0.37%)
F   13.57 (-0.15%)
MU   65.19 (-2.79%)
CGC   0.71 (-2.10%)
GE   106.76 (+0.64%)
DIS   92.50 (-0.02%)
AMC   4.70 (-0.63%)
PFE   38.99 (+0.26%)
PYPL   64.31 (+0.42%)
NFLX   405.90 (+1.53%)
QQQ   352.59 (+1.08%)
AAPL   180.03 (+1.24%)
MSFT   325.17 (+0.55%)
META   264.98 (+0.52%)
GOOGL   122.05 (-0.37%)
AMZN   123.96 (+2.25%)
TSLA   233.08 (+3.79%)
NVDA   386.95 (+3.26%)
NIO   7.69 (-0.90%)
BABA   86.34 (+1.24%)
AMD   121.01 (+2.70%)
T   16.04 (-0.37%)
F   13.57 (-0.15%)
MU   65.19 (-2.79%)
CGC   0.71 (-2.10%)
GE   106.76 (+0.64%)
DIS   92.50 (-0.02%)
AMC   4.70 (-0.63%)
PFE   38.99 (+0.26%)
PYPL   64.31 (+0.42%)
NFLX   405.90 (+1.53%)
QQQ   352.59 (+1.08%)
AAPL   180.03 (+1.24%)
MSFT   325.17 (+0.55%)
META   264.98 (+0.52%)
GOOGL   122.05 (-0.37%)
AMZN   123.96 (+2.25%)
TSLA   233.08 (+3.79%)
NVDA   386.95 (+3.26%)
NIO   7.69 (-0.90%)
BABA   86.34 (+1.24%)
AMD   121.01 (+2.70%)
T   16.04 (-0.37%)
F   13.57 (-0.15%)
MU   65.19 (-2.79%)
CGC   0.71 (-2.10%)
GE   106.76 (+0.64%)
DIS   92.50 (-0.02%)
AMC   4.70 (-0.63%)
PFE   38.99 (+0.26%)
PYPL   64.31 (+0.42%)
NFLX   405.90 (+1.53%)
QQQ   352.59 (+1.08%)
AAPL   180.03 (+1.24%)
MSFT   325.17 (+0.55%)
META   264.98 (+0.52%)
GOOGL   122.05 (-0.37%)
AMZN   123.96 (+2.25%)
TSLA   233.08 (+3.79%)
NVDA   386.95 (+3.26%)
NIO   7.69 (-0.90%)
BABA   86.34 (+1.24%)
AMD   121.01 (+2.70%)
T   16.04 (-0.37%)
F   13.57 (-0.15%)
MU   65.19 (-2.79%)
CGC   0.71 (-2.10%)
GE   106.76 (+0.64%)
DIS   92.50 (-0.02%)
AMC   4.70 (-0.63%)
PFE   38.99 (+0.26%)
PYPL   64.31 (+0.42%)
NFLX   405.90 (+1.53%)
LON:NCYT

Novacyt (NCYT) Share Forecast, Price & News

GBX 40.10
-1.78 (-4.24%)
(As of 04:34 PM ET)
Compare
Today's Range
40.10
42.65
50-Day Range
39.45
58
52-Week Range
38.20
179.95
Volume
36,933 shs
Average Volume
193,305 shs
Market Capitalization
£28.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NCYT stock logo

About Novacyt (LON:NCYT) Stock

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

Receive NCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter.

NCYT Stock News Headlines

Publication of Annual Report and AGM voting
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Novacyt approved for COVID and winter viruses PCR test
Your three-minute digest - The Times
See More Headlines

NCYT Price History

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
174
Year Founded
N/A

Profitability

Net Income
£-22,200,000.00
Net Margins
-122.29%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£21.04 million
Cash Flow
GBX 69.09 per share
Book Value
GBX 163 per share

Miscellaneous

Free Float
N/A
Market Cap
£28.32 million
Optionable
Not Optionable
Beta
-2.22

Key Executives

  • Mr. James Martin McCarthy (Age 57)
    CFO, Acting CEO, Company Sec. & Director
    Comp: $361.66k
  • Bryan Close
    Chief Operations Officer
  • Ms. Wendy Karban
    Group HR Mang.
  • Mr. David Franks
    Chief HR Officer
  • Paul Oladimeji
    Group Head of R&D
  • Mr. Gérald Ulrich
    Chief Exec. Officer of Bus. Devel.
  • Mr. Steve Gibson
    Group Financial Controller













NCYT Stock - Frequently Asked Questions

How have NCYT shares performed in 2023?

Novacyt's stock was trading at GBX 113 on January 1st, 2023. Since then, NCYT shares have decreased by 64.5% and is now trading at GBX 40.10.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Novacyt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Biocept (BIOC), Ecolab (ECL), genedrive (GDR), Geron (GERN), Immunic (IMUX), Tiziana Life Sciences (TILS), Verastem (VSTM), VYNE Therapeutics (VYNE), Antero Midstream (AM) and Aileron Therapeutics (ALRN).

What is Novacyt's stock symbol?

Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."

How do I buy shares of Novacyt?

Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Novacyt's stock price today?

One share of NCYT stock can currently be purchased for approximately GBX 40.10.

How much money does Novacyt make?

Novacyt (LON:NCYT) has a market capitalization of £28.32 million and generates £21.04 million in revenue each year. The company earns £-22,200,000.00 in net income (profit) each year or GBX (0.32) on an earnings per share basis.

How many employees does Novacyt have?

The company employs 174 workers across the globe.

How can I contact Novacyt?

The official website for the company is www.novacyt.com. The company can be reached via phone at 33 1 39 46 51 04.

This page (LON:NCYT) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -